SXDPEX:SW:SW-iShares STOXX Europe 600 Health Care UCITS ETF (DE) EUR (EUR)

ETF | Others |

Last Closing

USD 118.68

Change

0.00 (0.00)%

Market Cap

USD 0.44B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.03 (+0.25%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.02 (+0.07%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.37 (+1.38%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-573.00 (-6.86%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-103.00 (-1.98%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-20.60 (-1.27%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-16.00 (-0.73%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.53 (+0.71%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.68 (+0.62%)

USD 130,595.12B

ETFs Containing SXDPEX:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.37% 59% D- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.37% 59% D- 62% D
Trailing 12 Months  
Capital Gain 17.25% 63% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.25% 63% D 65% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.73% 53% F 54% F
Dividend Return 4.73% 53% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.71% 68% D+ 72% C
Risk Adjusted Return 82.80% 72% C 74% C
Market Capitalization 0.44B 56% F 51% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike